Drug Discovery

Vividion Therapeutics to expand capabilities with new R&D centre in US

Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.

Apollo Therapeutics and University of Oxford sign drug discovery partnership

Apollo Therapeutics has entered into a collaboration with the University of Oxford in the UK to propel drug discovery and development.

Lynch Regenerative Medicine secures funds to develop skin regeneration solutions

Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.

Merck launches GMP-compliant cell culture media line in China

Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.

Merck enhances ophthalmology portfolio with EyeBio acquisition

MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.

FDA grants fast track status for Full-Life’s prostate cancer treatment

The US Food and Drug Administration (FDA) has granted fast track designation for radiotherapeutics company Full-Life Technologies’ 225Ac-FL-020 to treat metastatic castration-resistant prostate cancer (mCRPC).

FDA approves Verona Pharma’s Ohtuvayre for COPD treatment

The US Food and Drug Administration (FDA) has granted approval for Verona Pharma’s Ohtuvayre (ensifentrine) as maintenance therapy for chronic obstructive pulmonary disease (COPD) in adults.

Juniper to distribute Caris Life Sciences’ molecular profiling services in MEA

Singapore-based Juniper Biologics has secured the distribution rights for Caris Life Sciences' advanced solid tumour molecular profiling services in the Middle East and Africa (MEA).

Yellowstone Biosciences launches to develop soluble bispecific cancer therapies

UK-based Yellowstone Biosciences has announced its launch with a £16.5m investment from Syncona to develop soluble bispecific T-cell receptor (TCR)-based therapies.